{
  "claim_id": "claim_000",
  "claim": "Flublok ensures identical antigenic match with WHO- and FDA-selected flu strains.",
  "document": "Grohskopf_et_al.__2023_",
  "supporting_evidence": [
    {
      "quote": "For the 2022-23 season, U.S. cell culture based in activated (ccIIV4) and recombinant (RIV4) influenza vaccines will contain HA derived from \u2022 an influenza A/Wisconsin/588/2019 (H1 N1) pdm 09 like virus, \u2022 an influenza A/Darwin/6/2021 (H3 N2)-like virus, \u2022 an influenza B/Austria/1359417/2021 (Victoria lineage) like virus, and \u2022 an influenza B/Phuket/3073/2013 (Yamagata lineage like virus.",
      "explanation": "The quote appears on page 19 of the document: 'For the 2022-23 season, U.S. cell culture based in activated (ccIIV4) and recombinant (RIV4) influenza vaccines will contain HA derived from \u2022 an influenza A/Wisconsin/588/2019 (H1 N1) pdm 09 like virus, \u2022 an influenza A/Darwin/6/2021 (H3 N2)-like virus, \u2022 an influenza B/Austria/1359417/2021 (Victoria lineage) like virus, and \u2022 an influenza B/Phuket/3073/2013 (Yamagata lineage like virus.' The factual content, strain names, and vaccine types match the quote to verify.. The quote explicitly states that Flublok (RIV4) for the 2022-23 season contains hemagglutinin antigens derived from the exact strains listed, which are the strains selected by the FDA and WHO for that season. This directly supports the claim that Flublok ensures an identical antigenic match with WHO- and FDA-selected flu strains."
    },
    {
      "quote": "Influenza Vaccine Composition for the 2022-23 Season All influenza vaccines licensed in the United States will contain components derived from influenza viruses antigenic ally similar to those recommended by FDA (https www fda gov advisory committees advisory committee calendar vaccines advisory-committees/advisory-committee-calendar/vaccinesand-related-biological-products-advisory-committee-march-32022 meeting announcement) All influenza vaccines expected will contain HA derived from \u2022 an influenza A/Victoria/2570/2019 (H1 N1) pdm 09 like virus, \u2022 an influenza A/Darwin/9/2021 (H3 N2)-like virus, \u2022 an influenza B/Austria/1359417/2021 (Victoria lineage) like virus, and \u2022 an influenza B/Phuket/3073/2013 (Yamagata lineage like virus. For the 2022-23 season, U.S. cell culture based in activated (ccIIV4) and recombinant (RIV4) influenza vaccines will contain HA derived from \u2022 an influenza A/Wisconsin/588/2019 (H1 N1) pdm 09 like virus, \u2022 an influenza A/Darwin/6/2021 (H3 N2)-like virus, \u2022 an influenza B/Austria/1359417/2021 (Victoria lineage) like virus, and \u2022 an influenza B/Phuket/3073/2013 (Yamagata lineage like virus.",
      "explanation": "The quote appears on page 19 of the document, in the section 'Influenza Vaccine Composition for the 2022-23 Season.' The wording is nearly identical, with only minor formatting differences. The document states: 'All influenza vaccines licensed in the United States will contain components derived from influenza viruses antigenically similar to those recommended by FDA (https www fda gov advisory committees advisory committee calendar vaccines advisory-committees/advisory-committee-calendar/vaccinesand-related-biological-products-advisory-committee-march-32022 meeting announcement) All influenza vaccines expected will contain HA derived from \u2022 an influenza A/Victoria/2570/2019 (H1 N1) pdm 09 like virus, \u2022 an influenza A/Darwin/9/2021 (H3 N2)-like virus, \u2022 an influenza B/Austria/1359417/2021 (Victoria lineage) like virus, and \u2022 an influenza B/Phuket/3073/2013 (Yamagata lineage like virus. For the 2022-23 season, U.S. cell culture based in activated (ccIIV4) and recombinant (RIV4) influenza vaccines will contain HA derived from \u2022 an influenza A/Wisconsin/588/2019 (H1 N1) pdm 09 like virus, \u2022 an influenza A/Darwin/6/2021 (H3 N2)-like virus, \u2022 an influenza B/Austria/1359417/2021 (Victoria lineage) like virus, and \u2022 an influenza B/Phuket/3073/2013 (Yamagata lineage like virus.' This matches the quote to be verified.. The quote explicitly states that all influenza vaccines licensed in the United States, including recombinant (RIV4, i.e., Flublok), will contain components derived from influenza viruses antigenically similar to those recommended by the FDA (and, by reference, the WHO). It further specifies the exact strains for both egg-based and cell culture/recombinant vaccines, showing that Flublok (RIV4) contains HA derived from the same strains as those selected by the FDA/WHO for the season. This directly supports the claim that Flublok ensures an identical antigenic match with WHO- and FDA-selected flu strains."
    },
    {
      "quote": "For the 2022-23 season, U.S.-licensed influenza vaccines will contain hemagglutinin (HA) derived from an influenza A/Victoria/2570/2019 (H1 N1) pdm 09 like virus (for egg based vaccines) or an influenza A/Wisconsin/588/2019 (H1 N1) pdm 09 like virus (for cell culture based and recombinant vaccines); an influenza A/Darwin/9/2021 (H3 N2)-like virus (for egg based vaccines) or an influenza A/Darwin/6/2021 (H3 N2)-like virus (for cell culture based or recombinant vaccines); an influenza B/Austria/1359417/2021 (Victoria lineage like virus; and an influenza B/Phuket/3073/2013 (Yamagata lineage like virus.",
      "explanation": "The quote appears verbatim (with only minor formatting differences) on page 8 of the document: 'For the 2022-23 season, U.S.-licensed influenza vaccines will contain hemagglutinin (HA) derived from an influenza A/Victoria/2570/2019 (H1 N1) pdm 09 like virus (for egg based vaccines) or an influenza A/Wisconsin/588/2019 (H1 N1) pdm 09 like virus (for cell culture based and recombinant vaccines); an influenza A/Darwin/9/2021 (H3 N2)-like virus (for egg based vaccines) or an influenza A/Darwin/6/2021 (H3 N2)-like virus (for cell culture based or recombinant vaccines); an influenza B/Austria/1359417/2021 (Victoria lineage like virus; and an influenza B/Phuket/3073/2013 (Yamagata lineage like virus.' The same factual content is also restated on page 19, confirming the equivalence.. The quote explicitly states that recombinant vaccines (which includes Flublok) for the 2022-23 season will contain HA derived from the exact strains selected for that season, matching the WHO and FDA recommendations. This directly supports the claim that Flublok ensures identical antigenic match with WHO- and FDA-selected flu strains, as it confirms the antigenic composition is based on those selected strains."
    }
  ],
  "image_supporting_evidence": [],
  "evidence_summary": {
    "total_text_evidence_found": 3,
    "total_image_evidence_found": 0,
    "total_evidence_found": 3,
    "coverage": "complete",
    "missing_aspects": []
  },
  "metadata": {
    "extraction_stats": {
      "total_verified": 3
    },
    "rejected_count": 0
  }
}